Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 2

Conditions

Neoplasms 2009Carcinoma, Non-Small-Cell Lung 1222Breast Neoplasms 1214Leukemia, Myeloid, Acute 965Neoplasm Metastasis 900Melanoma 777Colorectal Neoplasms 749Lymphoma 725Multiple Myeloma 723Ovarian Neoplasms 673Pancreatic Neoplasms 664Prostatic Neoplasms 657Lymphoma, Non-Hodgkin 657Recurrence 636Precursor Cell Lymphoblastic Leukemia-Lymphoma 583Lung Neoplasms 559Leukemia, Lymphocytic, Chronic, B-Cell 555Glioblastoma 527Leukemia 485Lymphoma, Large B-Cell, Diffuse 440Lymphoma, Follicular 418Brain Neoplasms 413Squamous Cell Carcinoma of Head and Neck 388Stomach Neoplasms 386Carcinoma, Renal Cell 384Myelodysplastic Syndromes 381Carcinoma, Hepatocellular 367Advanced Solid Tumors 356Lymphoma, Mantle-Cell 345Glioma 342

Interventions

capmatinib 2Rosuvastatin Calcium 1Midazolam 1Digoxin 1Caffeine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × cMET-dysregulated Advanced Solid Tumors × Clear all
NCT02520752 2020-12-10

A DDI Study to Assess the Effect of INC280 on the PK of Midazolam and Caffeine in Patients With cMET-dysregulated Advanced Solid Tumors

Novartis

Phase 1 Completed
37 enrolled
Other solid neoplasm

cMET-dysregulated Advanced Solid Tumors

NCT02626234 2020-12-10

A Drug-drug Interaction (DDI) Study to Assess the Effect of INC280 on the Pharmacokinetics of Digoxin and Rosuvastatin in Patients With cMET-dysregulated Advanced Solid Tumors

Novartis

Phase 1 Completed
32 enrolled
Other solid neoplasm

cMET-dysregulated Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡